<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="679">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04362943</url>
  </required_header>
  <id_info>
    <org_study_id>PAS-BAR-2020-04</org_study_id>
    <nct_id>NCT04362943</nct_id>
  </id_info>
  <brief_title>Clinical-epidemiological Characterization of COVID-19 Disease in Hospitalized Older Adults</brief_title>
  <acronym>COVID-AGE</acronym>
  <official_title>Clinical-epidemiological Characterization of COVID-19 Disease in Hospitalized Older Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Complejo Hospitalario Universitario de Albacete</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Complejo Hospitalario Universitario de Albacete</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Retrospective clinical-epidemiological study aimed at characterizing COVID-19 disease in&#xD;
      adults older than 70 years, hospitalized in the &quot;Perpetuo Socorro&quot; Hospital of Albacete&#xD;
      (Spain) from 09/03/2020 until 20/04/2020. Secondary objectives will be to analyze&#xD;
      clinical-epidemiological characteristics of COVID-19 patients treated with Baricitinib or&#xD;
      Anakinra, and to describe the efficacy and secondary effects of those drugs.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Design: Retrospective postauthorization study. Registry study. Setting: COVID Unit, &quot;Perpetuo&#xD;
      Socorro&quot; Hospital of Albacete (Spain). Participants: Adults older than 70 years hospitalized&#xD;
      for COVID-19 disease between 09/03/2020 and 20/04/2020. All patients will be included without&#xD;
      exclussion criteria.&#xD;
&#xD;
      Measurements:&#xD;
&#xD;
        -  Age, sex, residency.&#xD;
&#xD;
        -  Functional assessment: Barthel index, Katz index, Functional Ambulation Classification.&#xD;
&#xD;
        -  Cognitive assessment: Reisberg´s Global Deteriorating Scale.&#xD;
&#xD;
        -  Comorbidity: Charlson index, disease count.&#xD;
&#xD;
        -  Chronic medicines consumed.&#xD;
&#xD;
        -  Disease related symptoms.&#xD;
&#xD;
        -  Lab determinations: White cells, neutrophyl count, lymphocyte count, platelets,&#xD;
           haemoglobin, INR, fibrinogen, D-Dimer, Ferritin, CRP, IL-6, urea, creatinin, AST, ALT,&#xD;
           CK.&#xD;
&#xD;
        -  Thorax X-ray findings: COVID affectation, severity, pleural effusion, heart failure&#xD;
           signs, pneumothorax.&#xD;
&#xD;
        -  Drugs used during hospitalization, number of days of treatment and total doses:&#xD;
           Anakinra, Baricitinib, Glucocorticoids, Antivirals (Lopinavir/Ritonavir,&#xD;
           Emtricitabina/Tenofovir), Azitromycin, Ceftriaxone, Hidroxychloroquin.&#xD;
&#xD;
        -  Geriatric syndroms: Delirium, immobility, dysphagia, pressure ulcers.&#xD;
&#xD;
        -  Outcomes: Mortality at discharge, institucionalización at discharge, length of stay,&#xD;
           change in lab results, change in X-ray results, change in function at discharge.&#xD;
&#xD;
      Registry procedures: Medical chart review by trained Geriatricians, pharmachological chart&#xD;
      review by expert Pharmacists, X-ray review by trained radiologists. All data will be included&#xD;
      in an anonimyzed database for further analysis by investigators, and supervised by Principal&#xD;
      Investigator.&#xD;
&#xD;
      Regulatory status: The protocol was approved by the Ethics review committee of Albacete&#xD;
      (number 2020-21 from 20/04/2020) and by the Spanish Medicines Agency (AEMPS) who gave a&#xD;
      &quot;Postauthorization Study&quot; classification (number PAS-BAR-2020-04. 20/04/2020).&#xD;
&#xD;
      Analysis: Two stage analysis will be conducted. In first one, efficacy and security analysis&#xD;
      of the 99 patients that have received either Baricitinib or Anakinra will be conducted, and&#xD;
      in the second one, clinical-epidemiological analysis of the complete sample, n=576, will be&#xD;
      realized.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 20, 2020</start_date>
  <completion_date type="Anticipated">July 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">May 15, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Mortality</measure>
    <time_frame>1 month</time_frame>
    <description>Mortality for all causes</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>X-ray changes</measure>
    <time_frame>1 month</time_frame>
    <description>Changes from admission to discharge thorax X-rays assessed by blinded radiologists</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disability changes</measure>
    <time_frame>1 month</time_frame>
    <description>Changes from admission to discharge in Barthel index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ambulation changes</measure>
    <time_frame>1 month</time_frame>
    <description>Changes from admission to discharge in Functional Ambulation Classification</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>lymphocyte count changes</measure>
    <time_frame>1 month</time_frame>
    <description>Changes from admission to discharge in lymphocyte count</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C-Reactive Protein changes</measure>
    <time_frame>1 month</time_frame>
    <description>Changes from admission to discharge in C-Reactive Protein</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ferritin changes</measure>
    <time_frame>1 month</time_frame>
    <description>Changes from admission to discharge in Ferritin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>D-Dimer changes</measure>
    <time_frame>1 month</time_frame>
    <description>Changes from admission to discharge in D-Dimer</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">576</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Complete sample</arm_group_label>
    <description>Adults older than 70 years hospitalized for COVID-19 disease between 09/03/2020 and 20/04/2020 in the &quot;Perpetuo Socorro&quot; Hospital of Albacete (Spain)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Baricitinib</arm_group_label>
    <description>Adults older than 70 years hospitalized for COVID-19 disease between 09/03/2020 and 20/04/2020 and receiving Baricitinib.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Anakinra</arm_group_label>
    <description>Adults older than 70 years hospitalized for COVID-19 disease between 09/03/2020 and 20/04/2020 and receiving Anakinra.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Baricitinib or Anakinra</intervention_name>
    <description>Treatment with either Baricitinib or Anakinra during hospitalization, in real world, and under usual clinical care.</description>
    <arm_group_label>Anakinra</arm_group_label>
    <arm_group_label>Baricitinib</arm_group_label>
    <arm_group_label>Complete sample</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adults older than 70 years hospitalized for COVID-19 disease between 09/03/2020 and&#xD;
        20/04/2020, in the &quot;Perpetuo Socorro&quot; Hospital of Albacete (Spain).&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adults older than 70 years hospitalized for COVID-19 disease between 09/03/2020 and&#xD;
             20/04/2020, in the &quot;Perpetuo Socorro&quot; Hospital of Albacete (Spain).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  None&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>70 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pedro Abizanda Soler, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Head Geriatrics Department</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pedro Abizanda Soler, MD,PhD</last_name>
    <phone>+34636557437</phone>
    <email>pabizanda@sescam.jccm.es</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Almudena Avendaño Céspedes, RN, PhD</last_name>
    <phone>+34967597684</phone>
    <email>aavendanoc@sescam.jccm.es</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario de Albacete</name>
      <address>
        <city>Albacete</city>
        <zip>02006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pedro Abizanda Soler, MD,PhD</last_name>
      <phone>+34967597684</phone>
      <email>pabizanda@sescam.jccm.es</email>
    </contact>
    <contact_backup>
      <last_name>Almudena Avendaño Céspedes, RN, PhD</last_name>
      <phone>+34967597684</phone>
      <email>aavendanoc@sescam.jccm.es</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 22, 2020</study_first_submitted>
  <study_first_submitted_qc>April 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 27, 2020</study_first_posted>
  <last_update_submitted>April 23, 2020</last_update_submitted>
  <last_update_submitted_qc>April 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Complejo Hospitalario Universitario de Albacete</investigator_affiliation>
    <investigator_full_name>Pedro Abizanda</investigator_full_name>
    <investigator_title>Prof.</investigator_title>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <keyword>Older adults</keyword>
  <keyword>Hospitalization</keyword>
  <keyword>Baricitinib</keyword>
  <keyword>Anakinra</keyword>
  <keyword>Effectiveness</keyword>
  <keyword>Security</keyword>
  <keyword>Mortality</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interleukin 1 Receptor Antagonist Protein</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Data will be shared on request. Study protocol, statistical analysis and clinical study report will be shared when data will be published in a Journal.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>At data Journal publication</ipd_time_frame>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

